The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.
Christina Bennett, MS
The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising.
The phase II trial evaluated dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.
Avelumab alone or with pegylated liposomal doxorubicin did not improve survival in this phase III trial, but a subgroup analysis showed promising findings.
Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019.
Early results of the WISP trial, which is evaluating risk-reducing salpingo-oophorectomy vs salpingectomy with delayed oophorectomy, were presented in Honolulu.
In a phase IIIb trial, researchers evaluated the efficacy of an oral anticoagulant in cancer patients at high risk for venous thromboembolism.
A systematic review in JAMA Oncology examined the safety and efficacy of immune checkpoint inhibitors in advanced-stage cancer patients with HIV infection.
The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.
The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology.